Compared side by side

Tirzepatide vs liraglutide: how they differ

Reviewed How we check the libraryPublished by PepVault

The short answer

Liraglutide is a GLP-1 receptor agonist given as a daily shot, with a half-life of about 13 hours; tirzepatide activates the GLP-1 and GIP receptors and, with a half-life of about 5 days, is taken weekly. Both are FDA-approved, liraglutide as Victoza and Saxenda, tirzepatide as Mounjaro and Zepbound. Commonly reported: appetite drops and meals end sooner on liraglutide, less dramatically than on tirzepatide, whose appetite suppression users describe as very strong.

Side by side

ComparedTirzepatideLiraglutide
CategoryMetabolic & GLP-1Metabolic & GLP-1
Also known asMounjaro, Zepbound, LY3298176Victoza, Saxenda, Liraglutide injection
What it isThe first dual GIP/GLP-1 receptor agonist: it activates two gut-hormone pathways at once, and in a head-to-head trial it produced more weight loss than semaglutide (20.2% vs 13.7% at 72 weeks).The predecessor to semaglutide: a GLP-1 receptor agonist that reduces appetite and improves blood sugar control, given as a daily injection rather than weekly.
How it worksDual GIP/GLP-1 receptor agonist. Significantly reduces body weight through appetite suppression, slowed gastric emptying, and improved insulin sensitivity. Approved for T2DM and obesity management.GLP-1 receptor agonist and predecessor to semaglutide. Stimulates insulin secretion, reduces glucagon, slows gastric emptying, and reduces appetite. Shorter half-life than semaglutide requiring daily dosing. FDA approved for type 2 diabetes (Victoza) and obesity (Saxenda). The labels step the dose up from 0.6 mg to minimize GI side effects.
Commonly reportedVery strong appetite suppression and meals ending early, with nausea or tiredness for a day or two after the injection, mostly after dose increases. FDA-approved for diabetes (Mounjaro) and for weight management and sleep apnea (Zepbound).Appetite drops and meals end sooner, though less dramatically than on semaglutide or tirzepatide, with nausea during the climb to 3 mg. FDA-approved for diabetes (Victoza) and obesity (Saxenda), with one of the longest track records of any GLP-1 drug.
Studied rangeFDA label: 2.5–15 mg, starting dose 2.5 mg.FDA label: 0.6–3 mg, starting dose 0.6 mg.
How oftenWeeklyDaily SubQ
Half-life~5 days (FDA label)~13 hours
RouteSubQ injectionSubQ injection
Typical runFDA-approved for ongoing use. Titrate slowly upward. Community maintains on minimum effective dose.FDA-approved for daily use. Community uses continuously or until goal reached.
EvidenceEstablished: clinical trials or FDA-approved use existsEstablished: clinical trials or FDA-approved use exists
Common side effectsNausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigueNausea, vomiting, diarrhea, constipation, pancreatitis risk, thyroid C-cell tumor risk (animal data)

Typical run: Community practice — opinions vary. Not a clinical recommendation.

A smiling man in a grey t-shirt in his living room, holding his phone

Model. Individual results vary.

PepVault for iPhone

Taking tirzepatide or liraglutide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Week by week

Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.

Tirzepatide

  • Day 1–28 · 2.5 mg Getting your gut acclimated
  • Day 29–56 · 5 mg First therapeutic dose — weight drops
  • Day 57–112 · 7.5 mg Dual agonism in full effect
  • Day 113–168 · 12.5 mg Max titration reached
  • Day 169–504 Weeks 24 to 72: where most people plateau
  • Day 365+ A maintenance medication, not a course

Every card for tirzepatide, with its sources

Liraglutide

  • Day 1–14 · 0.6 mg Starting dose — GI is the main thing
  • Day 14–42 Titrating up — appetite really drops
  • Day 42–168 Steady loss at target dose
  • Day 168–365 Maintenance and long game

Every card for liraglutide, with its sources

Questions people ask

How long do tirzepatide and liraglutide last?

The half-life of tirzepatide is ~5 days (FDA label). The half-life of liraglutide is ~13 hours.

How often are tirzepatide and liraglutide taken?

Tirzepatide: weekly. Route: SubQ injection. Liraglutide: daily SubQ. Route: SubQ injection.

How are tirzepatide and liraglutide dosed in research?

The FDA label range for tirzepatide is 2.5–15 mg, with a 2.5 mg starting dose. The FDA label range for liraglutide is 0.6–3 mg, with a 0.6 mg starting dose.

What are the common side effects of tirzepatide and liraglutide?

For tirzepatide, the library lists: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue. For liraglutide: nausea, vomiting, diarrhea, constipation, pancreatitis risk, thyroid C-cell tumor risk (animal data).

Each one in full

Track it in the app

PepVault for iPhone

Taking tirzepatide or liraglutide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo